In July 2002, Aventis had announced the termination of patient enrollment in the Expedition trial involving the cardiovascular drug candidate cariporide, following a recommendation by an independent Drug Safety Monitoring Board. This trial was a phase III drug-intervention study in coronary artery bypass (CABG) patients.
Upon completion of the analysis of the overall benefit-risk assessment, Aventis has concluded that the results do not support a regulatory submission for cariporide.
Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2002, Aventis generated sales of € 17.6 billion, invested € 3.1 billion in research and development.